Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00049374
Other study ID # CDR0000258058
Secondary ID MSGCC-210421NCI-
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2002
Est. completion date January 2006

Study information

Verified date October 2019
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs.

PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in treating patients who have relapsed or refractory multiple myeloma.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
oblimersen sodium

Drug:
dexamethasone

thalidomide


Locations

Country Name City State
United States Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland
United States St. Vincent's Comprehensive Cancer Center - Manhattan New York New York

Sponsors (3)

Lead Sponsor Collaborator
University of Maryland, Baltimore National Cancer Institute (NCI), University of Maryland Greenebaum Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexameth — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Complete and partial remission
Secondary Relationship between molecular and clinical outcomes
See also
  Status Clinical Trial Phase
Completed NCT00568880 - Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT01137825 - Registry of Older Patients With Cancer
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00478075 - Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00313625 - Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00951626 - A Standardized Nursing Intervention Protocol for HCT Patients N/A
Terminated NCT00608517 - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil N/A
Completed NCT00898066 - S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease N/A
Completed NCT00301951 - Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Phase 1
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Completed NCT00937183 - Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma N/A
Completed NCT00004072 - O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00003396 - Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Phase 2
Completed NCT00003398 - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Phase 4
Completed NCT00003399 - Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma Phase 2
Active, not recruiting NCT00003163 - Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Phase 2
Terminated NCT00005641 - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Phase 2
Active, not recruiting NCT00002599 - Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Phase 3
Active, not recruiting NCT00002653 - Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Phase 3